Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 12/20 | 0.76 |
| ▸ | PYGM | P11217 | 12/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7123098 | 0.92 | PYGL (0.83) | PYGLPYGMKMT2ATDP1L3MBTL1 | |
| SCHEMBL7116414 | 0.86 | PYGL (0.74) | PYGLPYGMKMT2ATDP1L3MBTL1 | |
| SCHEMBL7118256 | 0.86 | PYGL (0.74) | PYGLPYGMKMT2ATDP1L3MBTL1 | |
| SCHEMBL7129418 | 0.86 | PYGL (0.74) | PYGLPYGMKMT2ATDP1L3MBTL1 | |
| SCHEMBL7126110 | 0.86 | PYGL (0.74) | PYGLPYGMKMT2ATDP1L3MBTL1 | |
| SCHEMBL6431424 | 0.86 | PYGL (0.74) | PYGLPYGMKMT2ATDP1L3MBTL1 | |
| SCHEMBL6431208 | 0.86 | PYGL (0.80) | PYGLPYGMTDP1HPSE | |
| SCHEMBL7126593 | 0.84 | PYGL (0.71) | PYGLPYGMKMT2ATDP1L3MBTL1 | |
| SCHEMBL7128870 | 0.84 | PYGL (0.70) | PYGLPYGMTDP1RAB9ALMNA | |
| SCHEMBL6438963 | 0.83 | PYGL (0.70) | PYGLPYGMKMT2ATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | KRISTIANSEN MARIT (DK) | 2003-10-02 | — | — | US | disclosed |
| US-6590118-B1 | Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) | NOVO NORDISK A/S (DK) | 2003-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | PYGL, GYS2, PYGM | PYGL 1/4885PYGM 3/4885KMT2A 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.